WO2007006544A3 - Cyclic adenosine monophosphate compounds for the treatment of immune-related disorders - Google Patents

Cyclic adenosine monophosphate compounds for the treatment of immune-related disorders Download PDF

Info

Publication number
WO2007006544A3
WO2007006544A3 PCT/EP2006/006761 EP2006006761W WO2007006544A3 WO 2007006544 A3 WO2007006544 A3 WO 2007006544A3 EP 2006006761 W EP2006006761 W EP 2006006761W WO 2007006544 A3 WO2007006544 A3 WO 2007006544A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
immune
related disorders
finding
adenosine monophosphate
Prior art date
Application number
PCT/EP2006/006761
Other languages
French (fr)
Other versions
WO2007006544A2 (en
Inventor
Ron Kooijman
Sarah Gerlo
Peggy Verdood
Original Assignee
Univ Bruxelles
Ron Kooijman
Sarah Gerlo
Peggy Verdood
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bruxelles, Ron Kooijman, Sarah Gerlo, Peggy Verdood filed Critical Univ Bruxelles
Publication of WO2007006544A2 publication Critical patent/WO2007006544A2/en
Publication of WO2007006544A3 publication Critical patent/WO2007006544A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention is related to the finding that certain analogues of cAMP such as 8-(4-chlorophenylthio)- 2'- O- methyladenosine- 3', 5'- cyclic monophosphate (8-pCPT-2'-O-Me-cAMP) specifically blocks the production of IL-10 in human T cells. It is also related to the finding that the production of other cytokines (e.g. IL-2, IL-4, IL-5, IL-6, IL-12 and IFN-gamma) is not affected by these analogues. The finding may be used as a treatment of conditions which respond to a reduced level of IL-10 and/or by a change in the balance of the Th1 and Th2 responses. It may be used in research and in testing for dysfunctional EPAC protein and IL-10 producing pathways.
PCT/EP2006/006761 2005-07-12 2006-07-11 Cyclic adenosine monophosphate compounds for the treatment of immune-related disorders WO2007006544A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2005/007550 2005-07-12
EP2005007550 2005-07-12

Publications (2)

Publication Number Publication Date
WO2007006544A2 WO2007006544A2 (en) 2007-01-18
WO2007006544A3 true WO2007006544A3 (en) 2007-05-18

Family

ID=35811681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006761 WO2007006544A2 (en) 2005-07-12 2006-07-11 Cyclic adenosine monophosphate compounds for the treatment of immune-related disorders

Country Status (1)

Country Link
WO (1) WO2007006544A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituted phosphorothioate nucleotide analogs
UY34536A (en) 2011-12-22 2013-07-31 Alios Biopharma Inc NUCLEOSIDS REPLACED, NUCLEOTID AND ANALOG OF THE SAME
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2020064597A1 (en) * 2018-09-24 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of epac1 activators for the treatment of chronic kidney diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208406A (en) * 1976-07-15 1980-06-17 Georges Cehovic Composition for the treatment and prevention of skin, eye and mucosal inflammation
WO2000066131A1 (en) * 1999-05-04 2000-11-09 E-L Management Corporation Anti-irritant compositions containing a cyclic 2'-deoxy-nucleotide
WO2003104250A1 (en) * 2002-06-07 2003-12-18 Kylix, B. V. New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
WO2005123755A2 (en) * 2004-06-18 2005-12-29 Lauras As Purine nucleotide derivatives
WO2006038865A1 (en) * 2004-10-01 2006-04-13 Betagenon Ab Nucleotide derivatives for the treatment of type 2 diabetes and other disorders
WO2006133128A2 (en) * 2005-06-07 2006-12-14 The Regents Of The University Of California INHIBITION OF EPAC, PHOSPHOLIPASE Cϵ, AND PHOSPHOLIPASE D TO TREAT PAIN

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208406A (en) * 1976-07-15 1980-06-17 Georges Cehovic Composition for the treatment and prevention of skin, eye and mucosal inflammation
WO2000066131A1 (en) * 1999-05-04 2000-11-09 E-L Management Corporation Anti-irritant compositions containing a cyclic 2'-deoxy-nucleotide
WO2003104250A1 (en) * 2002-06-07 2003-12-18 Kylix, B. V. New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
WO2005123755A2 (en) * 2004-06-18 2005-12-29 Lauras As Purine nucleotide derivatives
WO2006038865A1 (en) * 2004-10-01 2006-04-13 Betagenon Ab Nucleotide derivatives for the treatment of type 2 diabetes and other disorders
WO2006133128A2 (en) * 2005-06-07 2006-12-14 The Regents Of The University Of California INHIBITION OF EPAC, PHOSPHOLIPASE Cϵ, AND PHOSPHOLIPASE D TO TREAT PAIN

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
WO2007006544A2 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
WO2007006544A3 (en) Cyclic adenosine monophosphate compounds for the treatment of immune-related disorders
ATE490984T1 (en) METHOD FOR PRODUCTION AND EVALUATION OF CYTOTOXICITY OF KIR2DL NK RECEPTOR ANTIBODIES
Gleeson et al. Influence of training load on upper respiratory tract infection incidence and antigen‐stimulated cytokine production
Aliani et al. Precursors of chicken flavor. I. Determination of some flavor precursors in chicken muscle
WO2005063820A3 (en) Il-7 fusion proteins
EA200801372A1 (en) METHODS OF OBTAINING SUBSTITUTED PYRIMIDINES
DK1996028T3 (en) Solid enzyme formulations and processes for their preparation
WO2006019300A3 (en) Immune stimulatory infant nutrition
EA200701500A1 (en) METHODS OF OBTAINING PYRAZOLO [3,4-d] Pyrimidine esters
WO2007006870A3 (en) Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
WO2008082440A3 (en) Fluorescent nucleoside analogues
EP1660682A4 (en) ANTISENSE MODULATION OF p38 MITOGEN ACTIVATED PROTEIN KINASE EXPRESSION
Sagu et al. Comprehensive characterization and relative quantification of α-amylase/trypsin inhibitors from wheat cultivars by targeted HPLC-MS/MS
Baldissera et al. Relationship between behavioral alterations and activities of adenylate kinase and creatine kinase in brain of rats infected by Trypanosoma evansi
Kono et al. Dextran sodium sulfate alters cytokine production in macrophages in vitro
Lee et al. Administration of glucosylceramide ameliorated the memory impairment in aged mice
TWI327918B (en)
WO2006107421A3 (en) Preparation of platelet analogs
WO2005079458A3 (en) ENHANCEMENT OF Th2-DEPENDENT AND INFLAMMATORY RESPONSE
WO2015099102A1 (en) Zinc-containing sleep-improving agent, non-rem sleep time-increasing agent, and sedative
Uzenbaeva et al. Profiles and morphology of peripheral blood cells in three bat species of Karelia during hibernation
Islam et al. Expression patterns of host inflammatory cytokine genes during infestation with Haemaphysalis longicornis, a zoonotic Vector, in blood sucking periods
WO2004089982A3 (en) April variants and methods thereof
Kooijman et al. CYCLIC ADENOSINE MONOPHOSPHATE COMPOUNDS FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS
Chen et al. Proteomic response of the rat liver in differential swimming modes

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06754709

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06754709

Country of ref document: EP

Kind code of ref document: A2